基因基因突变和其他遗传缺陷在乳腺细胞病变:对疾病病理学和向疗法的影响
Yannick Chantran1, Peter Valent2, Michel Arock3
1Department of Biological Hematology, Pitié-Salpêtrière Hospital, DMU BioGem, AP-HP.Sorbonne University, Paris, France; Department of Biological Immunology, Saint-Antoine Hospital, DMU BioGem, AP-HP.Sorbonne University, Paris, France; Health Environmental Risk Assessment (HERA) Team, Centre of Research in Epidemiology and Statistics (CRESS), Inserm / INRAE, Faculty of Pharmacy, Université de Paris, Paris, France.
系统性巨细胞症 (SM) 通常涉及KIT D816V突变. 先进的SM可能有额外的遗传缺陷,可以通过下一代测序检测到,有助于诊断和治疗监测.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 系统性乳腺细胞瘤 (SM) 是一种骨髓状瘤,其特征是乳腺细胞积累.
- 激活KIT D816V的突变存在于90%以上的惰性SM病例中.
- 先进的SM变种可以在与骨髓性恶性瘤相关的基因中携带额外的遗传突变.
研究的目的:
- 对SM中KIT D816V突变的现有诊断和监测技术进行审查.
- 突出下一代测序在识别高级SM中额外的遗传缺陷方面的作用.
- 强调基于PCR的方法对突变负担量化的有用性.
主要方法:
- 使用基因特异性定量PCR (AS-qPCR) 检测KIT D816V突变.
- 通过滴滴数字PCR (ddPCR) 来量化KIT D816V突变负担.
- 应用下一代测序 (NGS) 来识别额外的遗传改变.
主要成果:
- 基特D816V突变是惰性SM的标志,在90%以上的患者中发现.
- 晚期SM可能伴随着其他骨髓性恶性瘤基因的并发突变.
- AS-qPCR和ddPCR是KIT D816V检测和量化的既定方法.
- 在先进的SM中,NGS能够进行全面的基因分析.
结论:
- 检测KIT D816V突变对于诊断MS至关重要.
- 定量PCR技术对于监测疾病负担和治疗反应至关重要.
- 下一代测序为先进的SM亚型提供了更深入的遗传洞察.
- 精确的分子诊断为MS患者提供了个性化的治疗策略.
更多相关视频
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
相关概念视频
Abnormal Proliferation
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
